103201-79-2

Basic information

• Product Name: (+)-(3R,7aS)-Tetrahydro-3-phenyl-3H,5H-pyrrolo1,2-coxaole-5-one
• Synonyms: (3R,7aS)-3-Phenyl-tetrahydro-pyrrolo[1,2-c]oxazol-5-one;(+)-(3R,7αS)-Tetrahydro-3-phenyl-3H,5H-pyrrolo1,2-coxaole-5-one;(+)-(3R,7aS)-Tetrahydro-3-phenyl-3H,5H-pyrrolo[1,2-c]oxazol-5-one;(3R,7aS)-Tetrahydro-3-phenyl-3H,5H-pyrrolo[1,2-c]oxazol-5-one;3H,5H-Pyrrolo[1,2-c]oxazol-5-one, tetrahydro-3-phenyl-, (3R,7aS)-;(3R,7aS)-3-phenyltetrahydropyrrolo[1,2-c]oxazol-5(1H)-one;(3R,7aS)-3-Phenyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one;(3R,7aS)-3-phenyltetrahydro-3H,5H-pyrrolo[1,2-c]oxazol-5-one
• CAS NO: 103201-79-2
• Molecular Formula: C₁₂H₁₃NO₂
• Molecular Weight: 203.2371
• Product Categories: pharmacetical;Heterocyclic Building Blocks
• Mol File: 103201-79-2.mol
• Article Data: 28

Chemical Properties

• Melting Point: <25 °C
• Boiling Point: 383.2 °C at 760 mmHg
• Flash Point: 185.6 °C
• Appearance: /
• Density: 1.25 g/cm³
• Vapor Pressure: 4.47E-06mmHg at 25°C
• Refractive Index: 1.608
• Storage Temp.: 2-8°C
• Solubility: Chloroform (Sparingly), Ethyl Acetate (Slightly)
• PKA: -1.61±0.40(Predicted)
• CAS DataBase Reference: (+)-(3R,7aS)-Tetrahydro-3-phenyl-3H,5H-pyrrolo1,2-coxaole-5-one(CAS DataBase Reference)
• NIST Chemistry Reference: (+)-(3R,7aS)-Tetrahydro-3-phenyl-3H,5H-pyrrolo1,2-coxaole-5-one(103201-79-2)
• EPA Substance Registry System: (+)-(3R,7aS)-Tetrahydro-3-phenyl-3H,5H-pyrrolo1,2-coxaole-5-one(103201-79-2)

Safety Data

• Hazardous Substances Data: 103201-79-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(+)-(3R,7aS)-Tetrahydro-3-phenyl-3H,5H-pyrrolo1,2-coxaole-5-one is used as a key intermediate in the synthesis of Boceprevir (B674500) and its analogs. Boceprevir is a hepatitis C virus (HCV) protease inhibitor, which plays a crucial role in the treatment of chronic hepatitis C infection. (+)-(3R,7aS)-Tetrahydro-3-phenyl-3H,5H-pyrrolo1,2-coxaole-5-one's unique structure and chirality are essential for the development of these therapeutic agents, as they contribute to the drug's efficacy and selectivity in targeting the viral protease enzyme.

InChI:InChI=1/C12H13NO2/c14-11-7-6-10-8-15-12(13(10)11)9-4-2-1-3-5-9/h1-5,10,12H,6-8H2/t10-,12+/m0/s1

Upstream product

• 100-52-7 benzaldehyde 
• 62400-75-3 pyroglutamol 
• 4931-66-2 methyl (S)-pyroglutamate 
• 6525-53-7 L-glutamic acid dimethyl ester 
• 98-79-3 L-Pyroglutamic acid 
• 104-15-4 toluene-4-sulfonic acid 
• 17342-08-4 (S)-Pyroglutaminol 
• 74936-93-9 (S)-5-oxopyrrolidine-2-carbonyl chloride 
• 56-86-0 L-glutamic acid 
• 7149-65-7 ethyl (S)-pyroglutamate 

Downstream Products

• 134107-65-6 (3R,7aS)-3-phenyl-3,7a-dihydro-1H-pyrrolo[1,2-c]oxazol-5-one 
• 254909-17-6 (2R,5S,7R)-7-cyanomethyl-8-oxo-2-phenyl-1-aza-3-oxa-bicyclo[3.3.0]octane 
• 195818-96-3 (+)-(2R,5S,7R)-1-aza-3-oxa-2-phenyl-7,7-di(phenylselenenyl)bicyclo<3.3.0>octan-8-one 
• 138231-10-4 (+)-(2R,5S,7R)-1-aza-3-oxa-2-phenyl-7-allylbicyclo<3.3.0>octan-8-one 
• 138078-57-6 (+)-(2R,5S,7S)-1-aza-3-oxa-2-phenyl-7-allylbicyclo<3.3.0>octan-8-one 
• 134037-88-0 (+)-(2R,5S,7R)-1-aza-3-oxa-2-phenyl-7-(phenylmethyl)bicyclo<3.3.0>octan-8-one 

Relevant articles and documents

Highly diastereoselective alkylation of a pyroglutamate derivative with an electrophile obtained from indole. Synthesis of a potential intermediate for the preparation of the natural sweetener (-)-Monatin

The synthesis of a potential intermediate for the preparation of the very intensive sweetening agent (-)-Monatin is described. The synthesis is based on a highly diastereoselective alkylation reaction of a pyroglutamate derivative with an electrophile obtained from indole.

INHIBITORS OF APOL1 AND METHODS OF USING SAME

The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).

ANTIMICROBIAL COMPOUNDS AND METHODS

The invention is directed to compounds that are active as antibacterial agents. The invention compounds are active against gram-positive and gram-negative bacteria and can be used to treat infections caused by gram-positive and gram-negative bacteria. Also disclosed are processes and intermediates for making the compounds.

BENZIMIDAZOLE-LINKED INDOLE COMPOUND ACTING AS NOVEL DIVALENT IAP ANTAGONIST

The present invention discloses a benzimidazole-linked indole compound acting as novel divalent IAP antagonist, specifically disclosing the compound shown in fomulas (I) or a pharmaceutically acceptable salt thereof.

ANTI-EGFR ANTIBODY DRUG CONJUGATES

The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.

NITROGEN-CONTAINING HETEROCYCLIC AMIDE COMPOUND AND PHARMACEUTICAL USE THEREOF

PROBLEM TO BE SOLVED: To provide a nitrogen-containing heterocyclic amide compound having pyruvate dehydrogenase kinase inhibitory activity, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same. SOLUTION: The present invention provides a compound of formula [I-a] or formula [II], or a pharmaceutically acceptable salt thereof (a bond of a dotted line: a single bond or a double bond. X1: C, N, O. X2: C, N. R1a: C1-4 alkyl, C1-4 alkyl carbonyl. R2: halogen, cyano, C1-4 alkyl. A1-A7: C, N, O. A8: C, N. R3, R4: H, C1-4 alkyl. Cy1: C4-6 cycloalkyl or the like. Cy2: C3-6 cycloalkyl or the like. m, t, w: 0, 1. n, r, v: 0, 1, 2.) SELECTED DRAWING: None COPYRIGHT: (C)2019,JPOandINPIT

Method for preparing hydrobromic acid teneligliptin

The invention provides a method for preparing hydrobromic acid teneligliptin. The method includes steps of preparing L-hydroxyproline; mixing the L-hydroxyproline and sodium bicarbonate with each other to obtain mixtures, dissolving the mixtures in water, adding acetone into the water, dropping di-tert-butyl dicarbonate into the water, carrying out room-temperature reaction overnight and then treating reaction products to obtain t-butyloxycarboryl-N-hydroxyproline; preparing t-butyloxycarboryl-N-4-oxo-proline from the t-butyloxycarboryl-N-hydroxyproline; preparing (2S)-4-oxo-2-(3-thiazolidine carbonyl)-1-pyrrolidine carboxylic acid tert-butyl ester from the t-butyloxycarboryl-N-4-oxo-proline; preparing compounds III from compounds IV; preparing compounds II from the compounds III; preparing compounds 1-(3-methyl-1-phenyl-1H-pyrazole-5-base) piperazine from the compounds II; preparing intermediates I; preparing the hydrobromic acid teneligliptin from the intermediates I. The method has the advantages that the method is low in cost, and the cost of the method is only two-thirds of the cost of an existing method in the prior art; the yield of the hydrobromic acid teneligliptin is higher than 95%, and the purity of the hydrobromic acid teneligliptin is higher than 98%.

Compounding method for LCZ696 midbody

The invention discloses a compounding method for a LCZ696 midbody. The compounding route is as follows: wherein R1 is Me, Et or i-Pr; X is Cl, Br or I; R2 is Ms, Ts or Tf. According to the compounding method for the LCZ696 midbody disclosed by the invention, the methylating difficulty is reduced, the midbody is configured and overturned through the consequent reaction, the proportion of the required configuration is greatly increased, the product yield, purity and use ratio are increased and the industrial large-scale production is benefited.

ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES

The invention relates to anti-CD98 antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

ANTI-EGFR ANTIBODY DRUG CONJUGATES

The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.